Assembly Biosciences(DE:V7B)
€19.00+0.34 (+7.22%)
DE:V7B
Assembly Biosciences financials statements
€19.00
At close:+0.34 (+7.22%)
Assembly Biosciences (V7B) Ratios
3 Followers
Assembly Biosciences Ratios
DE:V7B's free cash flow for Q2 2026 was $-15.49M. For the 2026 fiscal year, DE:V7B's free cash flow was increased by $0.00 and operating cash flow was $-15.49M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.22 | 2.42 | 3.41 | 5.95 | 9.59 |
| Quick Ratio | 5.22 | 2.42 | 3.49 | 5.95 | 9.59 |
| Cash Ratio | 1.20 | 0.80 | 0.51 | 3.22 | 2.84 |
| Solvency Ratio | -0.12 | -0.47 | -0.63 | -4.84 | -5.85 |
| Operating Cash Flow Ratio | -0.84 | -1.07 | 0.58 | -5.18 | -5.81 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 203.71M | $ 29.69M | $ 38.06M | $ 77.84M | $ 132.07M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.03 | 0.02 | 0.03 | 0.03 |
| Debt-to-Equity Ratio | 0.01 | 0.09 | 0.06 | 0.04 | 0.04 |
| Debt-to-Capital Ratio | 0.01 | 0.08 | 0.05 | 0.04 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.25 | 3.57 | 3.33 | 1.23 | 1.13 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.23 | 0.51 | 0.51 | 0.86 | 1.80 |
| Net Debt to EBITDA | 9.31 | 0.89 | 0.27 | 0.53 | 0.43 |
| Profitability Margins | |||||
| Gross Profit Margin | 99.82% | -96.12% | -582.67% | 0.00% | 100.00% |
| EBIT Margin | -8.47% | -139.72% | -902.50% | 0.00% | -1455.87% |
| EBITDA Margin | -8.29% | -139.26% | -896.22% | 0.00% | -1448.42% |
| Operating Profit Margin | -16.76% | -159.26% | -902.50% | 0.00% | -2121.65% |
| Pretax Profit Margin | -8.47% | -139.72% | -854.32% | 0.00% | -2116.82% |
| Net Profit Margin | -8.47% | -140.87% | -854.78% | 0.00% | -2076.35% |
| Continuous Operations Profit Margin | -8.47% | -140.87% | -854.78% | 0.00% | -2076.35% |
| Net Income Per EBT | 100.00% | 100.83% | 100.05% | 100.00% | 98.09% |
| EBT Per EBIT | 50.52% | 87.73% | 94.66% | 98.91% | 99.77% |
| Return on Assets (ROA) | -2.38% | -33.71% | -44.75% | -91.45% | -67.97% |
| Return on Equity (ROE) | -2.96% | -120.44% | -148.98% | -112.61% | -76.87% |
| Return on Capital Employed (ROCE) | -5.80% | -63.64% | -66.24% | -110.08% | -75.83% |
| Return on Invested Capital (ROIC) | -5.79% | -63.24% | -65.42% | -105.91% | -73.06% |
| Return on Tangible Assets | -2.38% | -33.71% | -44.75% | -91.45% | -67.97% |
| Earnings Yield | -1.61% | -42.40% | -135.94% | -147.92% | -128.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 74.23 | 71.30 | 166.58 | 0.00 | 18.61 |
| Payables Turnover | 0.11 | 95.61 | 106.07 | 27.71 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | -15.30 | 0.00 | 0.00 |
| Fixed Asset Turnover | 26.49 | 8.51 | 2.63 | 0.00 | 0.87 |
| Asset Turnover | 0.28 | 0.24 | 0.05 | 0.00 | 0.03 |
| Working Capital Turnover Ratio | 0.53 | 0.35 | 0.08 | 0.00 | 0.04 |
| Cash Conversion Cycle | -3308.38 | 1.30 | -25.11 | -13.17 | 19.61 |
| Days of Sales Outstanding | 4.92 | 5.12 | 2.19 | 0.00 | 19.61 |
| Days of Inventory Outstanding | 0.00 | 0.00 | -23.86 | 0.00 | 0.00 |
| Days of Payables Outstanding | 3313.29 | 3.82 | 3.44 | 13.17 | 0.00 |
| Operating Cycle | 4.92 | 5.12 | -21.67 | 0.00 | 19.61 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.67 | -8.51 | 4.97 | -20.94 | -25.90 |
| Free Cash Flow Per Share | -3.67 | -8.52 | 4.91 | -20.96 | -26.75 |
| Dividend Paid and CapEx Coverage Ratio | -622.62 | -1825.61 | 89.19 | -828.07 | -30.17 |
| Capital Expenditure Coverage Ratio | -622.62 | -1825.61 | 89.19 | -828.07 | -30.17 |
| Operating Cash Flow Coverage Ratio | -15.64 | -16.55 | 9.71 | -24.38 | -14.42 |
| Operating Cash Flow to Sales Ratio | -0.57 | -1.79 | 3.18 | 0.00 | -14.93 |
| Free Cash Flow Yield | -10.79% | -53.98% | 49.93% | -134.38% | -95.69% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -61.84 | -2.36 | -0.74 | -0.68 | -0.78 |
| Price-to-Sales (P/S) Ratio | 5.27 | 3.32 | 6.29 | 0.00 | 16.12 |
| Price-to-Book (P/B) Ratio | 1.84 | 2.84 | 1.10 | 0.76 | 0.60 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.26 | -1.85 | 2.00 | -0.74 | -1.05 |
| Price-to-Operating Cash Flow Ratio | -9.28 | -1.85 | 1.98 | -0.75 | -1.08 |
| Price-to-Earnings Growth (PEG) Ratio | 0.67 | 0.05 | 0.02 | 0.02 | -0.01 |
| Enterprise Value Multiple | -54.31 | -1.50 | -0.43 | -0.15 | -0.68 |
| Enterprise Value | 325.46M | 59.50M | 27.54M | 13.98M | 61.69M |
| EV to EBITDA | -54.31 | -1.50 | -0.43 | -0.15 | -0.68 |
| EV to Sales | 4.50 | 2.09 | 3.85 | 0.00 | 9.86 |
| EV to Free Cash Flow | -7.91 | -1.16 | 1.22 | -0.17 | -0.64 |
| EV to Operating Cash Flow | -7.92 | -1.16 | 1.21 | -0.17 | -0.66 |
| Tangible Book Value Per Share | 18.44 | 5.56 | 8.98 | 20.49 | 46.84 |
| Shareholders’ Equity Per Share | 18.44 | 5.56 | 8.98 | 20.49 | 46.84 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.01 | -0.00 | 0.00 | 0.02 |
| Revenue Per Share | 6.45 | 4.75 | 1.56 | 0.00 | 1.73 |
| Net Income Per Share | -0.55 | -6.69 | -13.38 | -23.08 | -36.00 |
| Tax Burden | 1.00 | 1.01 | 1.00 | 1.00 | 0.98 |
| Interest Burden | 1.00 | 1.00 | 0.95 | 1.00 | 1.45 |
| Research & Development to Revenue | 0.90 | 1.96 | 6.83 | 0.00 | 10.96 |
| SG&A to Revenue | 0.27 | 0.63 | 3.20 | 0.00 | 4.60 |
| Stock-Based Compensation to Revenue | 0.06 | 0.11 | 0.71 | 0.00 | 0.84 |
| Income Quality | 6.71 | 1.27 | -0.37 | 0.91 | 0.72 |
Currency in USD
